Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy

Postgrad Med J. 2024 Sep 22;100(1188):703-708. doi: 10.1093/postmj/qgae063.

Abstract

For metastatic prostate cancer, androgen deprivation therapy (ADT) is the key strategy to control the disease. However, after 18-24 months of treatment, most patients will progress from metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) even with ADT. Once patients enter into mCRPC, they face with significant declines in quality of life and a dramatically reduced survival period. Thus, doublet therapy, which combines ADT with new hormone therapy (NHT) or ADT with docetaxel chemotherapy, substitutes ADT alone and has become the "gold standard" for the treatment of mHSPC. In recent years, triplet therapy, which combines ADT with NHT and docetaxel chemotherapy, has also achieved impressive effects in mHSPC. This article provides a comprehensive review of the recent applications of the triplet therapy in the field of mHSPC.

Keywords: combination therapy; doublet therapy; metastatic hormone-sensitive prostate cancer; triplet therapy.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists* / therapeutic use
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Docetaxel* / administration & dosage
  • Docetaxel* / therapeutic use
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms, Castration-Resistant / drug therapy
  • Prostatic Neoplasms, Castration-Resistant / pathology
  • Quality of Life

Substances

  • Androgen Antagonists
  • Docetaxel
  • Antineoplastic Agents, Hormonal